<DOC>
	<DOCNO>NCT00007189</DOCNO>
	<brief_summary>The purpose trial test ability non-steroidal anti-inflammatory medication naproxen celecoxib delay prevent onset AD age-related cognitive decline .</brief_summary>
	<brief_title>Alzheimer 's Disease Anti-Inflammatory Prevention Trial ( ADAPT )</brief_title>
	<detailed_description>Considerable evidence suggest inflammation may play role neurodegenerative process Alzheimer 's disease ( AD ) , use non-steroidal anti-inflammatory drug may associate reduce occurrence AD . ADAPT randomize trial test ability non-steroidal anti-inflammatory medication naproxen celecoxib delay prevent onset AD age-related cognitive decline . This long-term trial run 5 7 year . The study sponsor National Institute Aging conduct Roskamp Institute Tampa , FL ; Veterans Affairs Puget Sound Health Care System University Washington , Seattle , WA ; Boston University School Medicine , Boston , MA ; Johns Hopkins Medical Institutions , Baltimore , MD ; Sun Health Research Institute , Phoenix , AZ ; University Rochester , Rochester , NY . At six site , goal enroll approximately 700 men woman , total 2,625 participant . Participants must 70 year age older , parent , brother , sister , , serious age-related memory loss , senility , dementia , Alzheimer 's disease . Participants ask take anti-inflammatory medication placebo ( inactive pill ) twice daily . Before enrol trial , participant ask go study site two medical evaluation . Once enrol , need go study site medical evaluation every six month participate telephone interview twice year average seven year follow-up .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Aged 70 year old . Family history parent , brother , sister , , serious agerelated memory loss , senility , dementia , Alzheimer 's disease . Study partner available provide information cognitive status participant assist monitor trial medication , need . Sufficient fluency write spoken English participate study visit neuropsychological test . Willingness limit use follow duration study : vitamin E ( dose great 400 IU per day ) , nonaspirin NSAIDs , histamine H2 receptor antagonist ( Tagamet , example ) , corticosteroid , antiinflammatory analgesic dos aspirin ( great 81 mg per day ) , Ginkgo biloba extract Ability intention participate regular study visit , opinion study physician . Provision inform consent . History peptic ulcer disease bleed obstruction . Clinically significant liver kidney disease . History hypersensitivity aspirin , ibuprofen , celecoxib , naproxen , NSAIDs . Use anticoagulant medication . Cognitive impairment dementia . Current alcohol abuse dependence</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>Anti-inflammatory drug</keyword>
</DOC>